ClinicalTrials.gg
CompletedNCT01515462TIGET-WASUpdated Apr 4, 2025Results posted

Gene Therapy for Wiskott-Aldrich Syndrome

A Phase 1/2 interventional study of TLT003 in Wiskott-Aldrich Syndrome (WAS), sponsored by Fondazione Telethon. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Fondazione Telethon · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2010, registered Dec 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Sex
All
01

Study summary

This is phase I/II protocol to evaluate the safety and efficacy of WAS gene transfer into hematopoietic stem/progenitor cells for the treatment of Wiskott Aldrich Syndrome.

Read the detailed description

Wiskott-Aldrich Syndrome (WAS) is an X-linked primary immunodeficiency caused by mutations in the WAS gene which encodes the WAS protein (WASP), a cytoskeletal regulator which is expressed exclusively in hematopoietic cells.

02

Conditions studied

  • Wiskott-Aldrich Syndrome (WAS)

Keywords

  • Lentiviral vector
  • Gene therapy
  • Wiskott-Aldrich Syndrome
  • TLT003
  • Previously GSK2696275
  • Previously OTL-103
03

In context

Wiskott-Aldrich Syndrome

41 studies on the registry are indexed under Wiskott-Aldrich Syndrome; 4 are open to participants now.

This study's enrollment of 8 is below the median of 20 across 29 interventional studies indexed under Wiskott-Aldrich Syndrome.

Browse Wiskott-Aldrich Syndrome studies →

Lead sponsor

Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of WAS defined by genetic mutation and at least one of the following criteria:

    • Severe WAS mutation
    • Absence of WASP expression
    • Severe clinical score (Zhu clinical score ≥ 3
  2. No HLA-identical sibling donor
  3. Negative search for a matched unrelated donor (10/10) or an adequate unrelated cord blood donor (5-6/6) within 4-6 months

    • Patients of > 5 years of age who are not candidate to unrelated transplant based on clinical conditions.
  4. Parental/guardian/patient signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients positive for -infection.
  2. Patients affected by neoplasia.
  3. Patients with cytogenetic alterations typical of MDS/AML.
  4. Patients with end-organ functions or any other severe disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study.
  5. Patients who underwent an haematopoietic stem cell transplantation in the previous 6 months.
  6. Patients who underwent an allogeneic haematopoietic stem cell transplantation with evidence of residual cells of donor origin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    TLT003 gene therapy

    Eligible subjects will receive intravenous (IV) infusion of TLT003 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included

    Genetic: TLT003

Interventions

  • GeneticTLT003

    TLT003 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein

    Also known as: Previously GSK2696275, Previously OTL-103

06

What researchers measure

Primary outcomes

  1. Safety of Reduced Conditioning Regimen

    The absence of prolonged aplasia (defined as ANC \<0.5×10\^9/L \[\<500/μL\] at Day +60, with no evidence of BM recovery and requiring backup administration) was assumed as demonstrating the safety of the RIC regimen.

    Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)

  2. Safety of Lentivirus Gene Transfer Into HSC

    Safety and tolerability of lentiviral-transduced cell infusion. This will be evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion.

    Time frame: after 48 hours after Telethon003 infusion

  3. Sustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow

    Engraftment is characterized by the presence of gene modified cells in the BM or PB compartments. The main indicator of gene correction is detection of the WAS LVV sequences in the HSPCs and their progeny. The VCN, which is the mean number of integrated copies of the vector sequences per cell genome, was measured using PCR-based methods in DNA samples extracted from BM and PB cell populations at various timepoints post-treatment. Adequate engraftment was defined as either ≥0.04 VCN/cell in BM CD34+ cells or ≥0.01 VCN/cell in PB CD3+ cells.

    Time frame: at 1 year after Telethon003 infusion

  4. Presence of Detectable Vector-derived WASP

    The percentage of subjects who present the proportion of PB cells expressing WASP was assessed by flow cytometry analysis.

    Time frame: Median duration: 11.1 years (range: 8.01 -13.3 years)

  5. Improved T-cell Functions

    Improvement in in vitro T-cell proliferation was assessed upon stimulation with 3 doses of anti-immobilized CD3 (CD3i) monoclonal antibodies ≥1 year after Telethon003 infusion (as compared with pre-GT values) in PBMC and/or T-cell lines. The degree of correction was evaluated with respect to healthy controls.

    Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)

  6. Antigen-specific Responses to Vaccination

    The ability to mount a protective humoral response to at least 4 out of 5 nominal antigens including antibodies to T-cell dependent antigens and conjugated or unconjugated polysaccharide antigens was measured after vaccination (planned \>1 year after Telethon003 infusion). If results were available on n \<5 antigens, the rule of at least n-1 applied to define success.

    Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)

  7. Improved Platelet Count and MPV Normalization

    Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile

    Time frame: up to 3 years after Telethon003 infusion

  8. Overall Survival

    Participant survival was monitored throughout the study.

    Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)

Secondary outcomes

  1. Lack of Immune Response to Transgene

    Anti-WASP and anti-HIV-1 antibodies (anti-p24) were monitored to evaluate response to transgene and to vector, respectively.

    Time frame: up to 3 years after Telethon003 infusion

  2. Reduced Frequency of Severe Infections

    Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.

    Time frame: up to 3 years after Telethon003 infusion

  3. Reduced Bruising and Bleeding Episodes

    Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history

    Time frame: 3 years

  4. Reduced Autoimmunity Phenomena and Eczema

    Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score

    Time frame: 3 years

  5. Improved Quality of Life

    Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.

    Time frame: 3 year

  6. Multilineage Engraftment of Genetically Corrected Cells

    ≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)

    Time frame: 3 years

  7. Overall Safety of the Treatment

    Recording of AE, AR, SAE/SAR, UAR, SUSAR

    Time frame: 8 years

07

Results

Posted Apr 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneOTL-103 Gene Therapy
Started8
Completed8
Not completed0

Outcome measures

PrimarySafety of Reduced Conditioning Regimen

The absence of prolonged aplasia (defined as ANC \<0.5×10\^9/L \[\<500/μL\] at Day +60, with no evidence of BM recovery and requiring backup administration) was assumed as demonstrating the safety of the RIC regimen.

Time frame:
Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Reported as:
Count of participants · Participants
Safety of Reduced Conditioning Regimen
ParticipantsTLT003 Gene Therapy
Safety of Reduced Conditioning Regimen8
PrimarySafety of Lentivirus Gene Transfer Into HSC

Safety and tolerability of lentiviral-transduced cell infusion. This will be evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion.

Time frame:
after 48 hours after Telethon003 infusion
Reported as:
Count of participants · Participants
Safety of Lentivirus Gene Transfer Into HSC
ParticipantsTLT003 Gene Therapy
Safety of Lentivirus Gene Transfer Into HSC8
PrimarySustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow

Engraftment is characterized by the presence of gene modified cells in the BM or PB compartments. The main indicator of gene correction is detection of the WAS LVV sequences in the HSPCs and their progeny. The VCN, which is the mean number of integrated copies of the vector sequences per cell genome, was measured using PCR-based methods in DNA samples extracted from BM and PB cell populations at various timepoints post-treatment. Adequate engraftment was defined as either ≥0.04 VCN/cell in BM CD34+ cells or ≥0.01 VCN/cell in PB CD3+ cells.

Time frame:
at 1 year after Telethon003 infusion
Reported as:
Count of participants · Participants
Sustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow
ParticipantsTLT003 Gene Therapy
Sustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow8
PrimaryPresence of Detectable Vector-derived WASP

The percentage of subjects who present the proportion of PB cells expressing WASP was assessed by flow cytometry analysis.

Time frame:
Median duration: 11.1 years (range: 8.01 -13.3 years)
Reported as:
Count of participants · Participants
Presence of Detectable Vector-derived WASP
ParticipantsTLT003 Gene Therapy
Presence of Detectable Vector-derived WASP8
PrimaryImproved T-cell Functions

Improvement in in vitro T-cell proliferation was assessed upon stimulation with 3 doses of anti-immobilized CD3 (CD3i) monoclonal antibodies ≥1 year after Telethon003 infusion (as compared with pre-GT values) in PBMC and/or T-cell lines. The degree of correction was evaluated with respect to healthy controls.

Time frame:
Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Reported as:
Count of participants · Participants
Improved T-cell Functions
ParticipantsTLT003 Gene Therapy
Improved T-cell Functions8
PrimaryAntigen-specific Responses to Vaccination

The ability to mount a protective humoral response to at least 4 out of 5 nominal antigens including antibodies to T-cell dependent antigens and conjugated or unconjugated polysaccharide antigens was measured after vaccination (planned \>1 year after Telethon003 infusion). If results were available on n \<5 antigens, the rule of at least n-1 applied to define success.

Time frame:
Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Reported as:
Number · participants
Antigen-specific Responses to Vaccination
participantsTLT003 Gene Therapy
Antigen-specific Responses to Vaccination7
PrimaryImproved Platelet Count and MPV Normalization

Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile

Time frame:
up to 3 years after Telethon003 infusion
Reported as:
Count of participants · Participants
Improved Platelet Count and MPV Normalization
ParticipantsTLT003 Gene Therapy
Improved Platelet Count and MPV Normalization8
PrimaryOverall Survival

Participant survival was monitored throughout the study.

Time frame:
Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsTLT003 Gene Therapy
Overall Survival8
SecondaryLack of Immune Response to Transgene

Anti-WASP and anti-HIV-1 antibodies (anti-p24) were monitored to evaluate response to transgene and to vector, respectively.

Time frame:
up to 3 years after Telethon003 infusion
Reported as:
Count of participants · Participants
Lack of Immune Response to Transgene
ParticipantsTLT003 Gene Therapy
Lack of Immune Response to Transgene8
SecondaryReduced Frequency of Severe Infections

Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.

Time frame:
up to 3 years after Telethon003 infusion

Results for this outcome have not been posted.

SecondaryReduced Bruising and Bleeding Episodes

Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryReduced Autoimmunity Phenomena and Eczema

Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryImproved Quality of Life

Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.

Time frame:
3 year

Results for this outcome have not been posted.

SecondaryMultilineage Engraftment of Genetically Corrected Cells

≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)

Time frame:
3 years

Results for this outcome have not been posted.

SecondaryOverall Safety of the Treatment

Recording of AE, AR, SAE/SAR, UAR, SUSAR

Time frame:
8 years

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were reported in the statistical outputs from Screening onward. Post-treatment AEs were recorded during follow up - Median duration of follow-up was 11.1 (range: 8.0-13.3) years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTL-103 Gene Therapy0/8 (0%)8/8 (100%)8/8 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventOTL-103 Gene Therapy
PyrexiaGeneral disorders3/8
Device related infectionInfections and infestations2/8
Mesenteric lymphadenitisBlood and lymphatic system disorders1/8
NeutropeniaBlood and lymphatic system disorders1/8
VomitingGastrointestinal disorders1/8
Food AllergyImmune system disorders1/8
GastroenteritisInfections and infestations1/8
Pneumonia aspirationInfections and infestations1/8
AppendicitisInfections and infestations1/8
Aspergillus infectionInfections and infestations1/8
Most frequent other events
Showing 10 of 334
Most frequent other events
EventOTL-103 Gene Therapy
PyrexiaGeneral disorders8/8
Upper respiratory tract infectionInfections and infestations8/8
Anti-platelet antibody positiveInvestigations8/8
DiarrhoeaGastrointestinal disorders7/8
PetechiaeSkin and subcutaneous tissue disorders7/8
RhinitisInfections and infestations6/8
HypokalaemiaMetabolism and nutrition disorders6/8
EczemaSkin and subcutaneous tissue disorders6/8
Ear infectionInfections and infestations5/8
InfluenzaInfections and infestations5/8

Baseline characteristics

paediatric population

Age, Categorical
Age, Categorical(Participants)OTL-103 Gene Therapy
<=18 years8
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)OTL-103 Gene Therapy
Female0
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTL-103 Gene Therapy
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTL-103 Gene Therapy
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)OTL-103 Gene Therapy
Italy8
08

Study locations

1 site
  • Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)
    Milan, 20132, Italy
09

References and documents

Publications

  • Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee PP, Orange JS, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013 Aug 23;341(6148):1233151. doi: 10.1126/science.1233151. Epub 2013 Jul 11. PubMed 23845947 ↗
  • Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009 Jan 29;360(5):447-58. doi: 10.1056/NEJMoa0805817. PubMed 19179314 ↗
  • Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program. 2009:682-9. doi: 10.1182/asheducation-2009.1.682. PubMed 20008254 ↗
  • Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009 Jun 18;113(25):6288-95. doi: 10.1182/blood-2008-12-115253. Epub 2009 Apr 7. PubMed 19351959 ↗
  • Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5. PubMed 17078381 ↗
  • Burns S, Cory GO, Vainchenker W, Thrasher AJ. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood. 2004 Dec 1;104(12):3454-62. doi: 10.1182/blood-2004-04-1678. Epub 2004 Aug 12. PubMed 15308573 ↗
  • Charrier S, Dupre L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O, Cattaneo F, Aiuti A, Eckenberg R, Thrasher AJ, Roncarolo MG, Galy A. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 2007 Mar;14(5):415-28. doi: 10.1038/sj.gt.3302863. Epub 2006 Oct 19. PubMed 17051251 ↗
  • Dupre L, Trifari S, Follenzi A, Marangoni F, Lain de Lera T, Bernad A, Martino S, Tsuchiya S, Bordignon C, Naldini L, Aiuti A, Roncarolo MG. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther. 2004 Nov;10(5):903-15. doi: 10.1016/j.ymthe.2004.08.008. PubMed 15509508 ↗
  • Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002 Jan 20;13(2):243-60. doi: 10.1089/10430340252769770. PubMed 11812281 ↗
  • Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008 Feb;8(2):181-90. doi: 10.1517/14712598.8.2.181. PubMed 18194074 ↗
  • Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, Panaroni C, Ponzoni M, Sanvito F, Doglioni C, Liabeuf M, Gjata B, Montus M, Siminovitch K, Aiuti A, Naldini L, Dupre L, Roncarolo MG, Galy A, Villa A. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther. 2009 Jun;17(6):1073-82. doi: 10.1038/mt.2009.31. Epub 2009 Mar 3. PubMed 19259069 ↗
  • Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, Strina D, Patrosso MC, Ramenghi U, Sacco MG, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995 Apr;9(4):414-7. doi: 10.1038/ng0495-414. PubMed 7795648 ↗
  • Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S2352-3026(19)30021-3. Epub 2019 Apr 10. PubMed 30981783 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Oct 2023, 161 months.

Results were first posted in Apr 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2011
First posted
Jan 24, 2012
StartActual
Apr 20, 2010
Primary completionActual
Oct 4, 2023
CompletionActual
Oct 4, 2023
Results first posted
Apr 4, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01515462
Lead sponsor
Fondazione Telethon
Collaborators
Ospedale San Raffaele
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
Apr 20, 2010
Primary completion
Oct 4, 2023
Completion
Oct 4, 2023
Results posted
Apr 4, 2025
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion